CL2023003001A1 - Novedosas proteínas de la cápside del virus adenoasociado - Google Patents

Novedosas proteínas de la cápside del virus adenoasociado

Info

Publication number
CL2023003001A1
CL2023003001A1 CL2023003001A CL2023003001A CL2023003001A1 CL 2023003001 A1 CL2023003001 A1 CL 2023003001A1 CL 2023003001 A CL2023003001 A CL 2023003001A CL 2023003001 A CL2023003001 A CL 2023003001A CL 2023003001 A1 CL2023003001 A1 CL 2023003001A1
Authority
CL
Chile
Prior art keywords
capsid proteins
associated virus
novel
virus capsid
novel adeno
Prior art date
Application number
CL2023003001A
Other languages
English (en)
Inventor
Lochrie Michael
Ng Robert
Cameron Colosi Peter
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of CL2023003001A1 publication Critical patent/CL2023003001A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4707—Muscular dystrophy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

La invención se refiere a novedosas proteínas de la cápside del virus adenoasociado (AAV), partículas de AAV que comprenden una novedosa proteína de la cápside, polinucleótidos que codifican estas proteínas de la cápside y vectores de AAV que expresan estas proteínas de la cápside. La invención también se refiere a métodos para elaborar los vectores de AAV descritos en la presente que expresan las novedosas proteínas de la cápside de la invención y sus usos terapéuticos asociados.
CL2023003001A 2016-07-26 2023-10-06 Novedosas proteínas de la cápside del virus adenoasociado CL2023003001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662366838P 2016-07-26 2016-07-26

Publications (1)

Publication Number Publication Date
CL2023003001A1 true CL2023003001A1 (es) 2024-04-19

Family

ID=59558468

Family Applications (6)

Application Number Title Priority Date Filing Date
CL2019000167A CL2019000167A1 (es) 2016-07-26 2019-01-22 Novedosas proteínas de la cápside del virus adenoasociado.
CL2020003176A CL2020003176A1 (es) 2016-07-26 2020-12-04 Novedosas proteínas de la cápside del virus adenoasociado (divisional sol. 201900167).
CL2023000165A CL2023000165A1 (es) 2016-07-26 2023-01-18 Novedosas proteínas de la cápside del virus adenoasociado
CL2023002764A CL2023002764A1 (es) 2016-07-26 2023-09-15 Novedosas proteínas de la cápside del virus adenoasociado
CL2023003001A CL2023003001A1 (es) 2016-07-26 2023-10-06 Novedosas proteínas de la cápside del virus adenoasociado
CL2023003010A CL2023003010A1 (es) 2016-07-26 2023-10-06 Novedosas proteínas de la cápside del virus adenoasociado

Family Applications Before (4)

Application Number Title Priority Date Filing Date
CL2019000167A CL2019000167A1 (es) 2016-07-26 2019-01-22 Novedosas proteínas de la cápside del virus adenoasociado.
CL2020003176A CL2020003176A1 (es) 2016-07-26 2020-12-04 Novedosas proteínas de la cápside del virus adenoasociado (divisional sol. 201900167).
CL2023000165A CL2023000165A1 (es) 2016-07-26 2023-01-18 Novedosas proteínas de la cápside del virus adenoasociado
CL2023002764A CL2023002764A1 (es) 2016-07-26 2023-09-15 Novedosas proteínas de la cápside del virus adenoasociado

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2023003010A CL2023003010A1 (es) 2016-07-26 2023-10-06 Novedosas proteínas de la cápside del virus adenoasociado

Country Status (15)

Country Link
US (2) US11584780B2 (es)
EP (1) EP3491008A2 (es)
JP (4) JP6994018B2 (es)
KR (2) KR20230161535A (es)
CN (1) CN109715650B (es)
AU (2) AU2017301600B2 (es)
BR (1) BR112019001532A2 (es)
CA (1) CA3031026A1 (es)
CL (6) CL2019000167A1 (es)
IL (2) IL263801B2 (es)
MX (1) MX2019000962A (es)
PE (1) PE20190401A1 (es)
PH (1) PH12019500068A1 (es)
SG (1) SG11201811603WA (es)
WO (1) WO2018022608A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
ES2865487T3 (es) 2015-09-28 2021-10-15 Univ North Carolina Chapel Hill Métodos y composiciones para vectores virales que evaden los anticuerpos
CN110225975A (zh) 2016-08-23 2019-09-10 阿库斯股份有限公司 用于治疗人受试者中非年龄相关的听力损害的组合物和方法
JP7498665B2 (ja) * 2018-02-27 2024-06-12 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規アデノ随伴ウイルス（ａａｖ）ベクター、低減されたカプシド脱アミド化を有するａａｖベクター、およびその使用
KR20210006357A (ko) 2018-04-03 2021-01-18 스트라이드바이오 인코포레이티드 항체-회피 바이러스 벡터
KR20210015770A (ko) * 2018-04-05 2021-02-10 제네똥 감소된 간 향성을 갖는 AAV9과 AAVrh74의 하이브리드 재조합 아데노-관련 바이러스 세로타입
TW202016314A (zh) 2018-05-09 2020-05-01 美商拜奧馬林製藥公司 治療苯丙酮尿症之方法
US11987801B2 (en) 2018-05-11 2024-05-21 Massachusetts Eye And Ear Infirmary Altering tissue tropism of adeno-associated viruses
TW202005978A (zh) * 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US11821009B2 (en) 2018-05-15 2023-11-21 Cornell University Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery
EP3841109A4 (en) * 2018-08-21 2022-09-21 Massachusetts Eye and Ear Infirmary COMPOSITIONS AND METHODS FOR MODULATING TRANSDUCTION EFFICIENCY OF ADENO-ASSOCIATED VIRUSES
AU2019391042A1 (en) * 2018-12-05 2021-06-10 Abeona Therapeutics Inc. Recombinant adeno-associated viral vector for gene delivery
CA3125294A1 (en) * 2019-01-23 2020-07-30 University Of Florida Research Foundation, Incorporated Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design
KR20220011616A (ko) 2019-03-21 2022-01-28 스트라이드바이오 인코포레이티드 재조합 아데노 관련 바이러스 벡터
US20220195458A1 (en) * 2019-03-28 2022-06-23 The General Hospital Corporation Engineered adeno-associated (aav) vectors for transgene expression
WO2020232044A1 (en) 2019-05-14 2020-11-19 Biomarin Pharmaceutical Inc. Methods of redosing gene therapy vectors
WO2021073568A1 (en) * 2019-10-16 2021-04-22 Wuxi Apptec (Shanghai) Co., Ltd. A novel aav variant
EP4045525A1 (en) 2019-10-17 2022-08-24 Stridebio, Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
TW202128733A (zh) 2019-11-14 2021-08-01 美商拜奧馬林製藥公司 使用肝特異性基因療法載體之遺傳性血管性水腫的治療
MX2022010050A (es) 2020-02-21 2022-09-05 Akouos Inc Composiciones y metodos para tratar deficiencia auditiva no asociada con la edad en un sujeto humano.
WO2021168509A1 (en) * 2020-02-25 2021-09-02 Children's Medical Research Institute Adeno-associated virus capsid polypeptides and vectors
WO2021183895A1 (en) 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors
AR122409A1 (es) 2020-04-03 2022-09-07 Biomarin Pharm Inc Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
AR121954A1 (es) 2020-04-29 2022-07-27 Bristol Myers Squibb Co Distrofinas miniaturizadas con dominios de fusión de espectrina y usos de las mismas
WO2021236908A2 (en) 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus
EP4176064A1 (en) * 2020-07-03 2023-05-10 Genethon Method for engineering novel hybrid aav capsids through hypervariable regions swapping
BR112023004176A2 (pt) * 2020-09-10 2023-04-11 Genethon Capsídeo de aav modificado por peptídeo
WO2022082109A1 (en) * 2020-10-18 2022-04-21 The Trustees Of The University Of Pennsylvania Improved adeno-associated virus (aav) vector and uses therefor
AU2021372262A1 (en) 2020-11-02 2023-06-01 Biomarin Pharmaceutical Inc. Process for enriching adeno-associated virus
WO2023034980A1 (en) 2021-09-03 2023-03-09 Bomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034994A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034997A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034996A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034990A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023034989A1 (en) 2021-09-03 2023-03-09 Biomarin Pharmaceutical Inc. Aav capsid compositions and methods for delivery
WO2023056436A2 (en) 2021-10-01 2023-04-06 Biomarin Pharmaceutical Inc. Treatment of hereditary angioedema with aav gene therapy vectors and therapeutic formulations
CN114276419B (zh) * 2021-12-30 2023-11-17 上海勉亦生物科技有限公司 肌肉高亲和性的新型腺相关病毒衣壳蛋白及其应用
WO2023183623A1 (en) * 2022-03-25 2023-09-28 Regenxbio Inc. Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
WO2024064856A1 (en) 2022-09-22 2024-03-28 Biomarin Pharmaceutical Inc. Treatment of cardiomyopathy with aav gene therapy vectors
WO2024064863A2 (en) 2022-09-22 2024-03-28 Biomarin Pharmaceutical Inc. Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
CN115925819B (zh) * 2022-12-30 2023-10-13 广州派真生物技术有限公司 腺相关病毒突变体及其应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58011B1 (en) 1983-05-27 1993-06-16 Texas A & M Univ Sys Method for producing a recombinant baculovirus expression vector
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
RU2273645C9 (ru) 1994-08-17 2006-11-27 Дзе Рокефеллер Юниверсити Полипептид ожирения (ов)(варианты), его аналог (варианты) и слитый белок (варианты), изолированная молекула нуклеиновой кислоты, молекула днк, рекомбинантный вектор клонирования, рекомбинантный вектор экспрессии, фармацевтическая композиция, моноклональное и поликлональное антитело
EP0931158A1 (en) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
JP2001500376A (ja) 1996-09-06 2001-01-16 カイロン コーポレイション 組換えａａｖベクターを使用する治療分子の肝臓特異的送達のための方法および組成物
WO1999003496A1 (en) 1997-07-21 1999-01-28 The University Of North Carolina At Chapel Hill Factor ix antihemophilic factor with increased clotting activity
EP1071752B1 (en) 1998-04-21 2003-07-09 Micromet AG CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
JP2004514407A (ja) 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異種キャプシド中にシュードタイピングされたａａｖ５キャプシドおよびａａｖ５ベクターを含む組換えａａｖベクター
CA2470711C (en) 2001-10-16 2011-07-12 National Institute Of Advanced Industrial Science And Technology Novel n-acetylglucosamine transferase, nucleic acid encoding the same, antibody against the same and use thereof for diagnosing cancer or tumor
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
HU230406B1 (hu) 2001-11-13 2016-04-28 The Trustees Of The University Of Pennsylvania Eljárás adeno-asszociált vírus(AAV)szekvenciák detektálására és/vagy azonosítására és az azzal azonosított új szekvenciák izolálására
EP3339430A1 (en) 2001-12-17 2018-06-27 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses thereof
AU2003212708A1 (en) 2002-03-05 2003-09-16 Stichting Voor De Technische Wetenschappen Baculovirus expression system
US20030198620A1 (en) 2002-04-16 2003-10-23 Keiya Ozawa Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions
WO2003093436A2 (en) 2002-04-30 2003-11-13 University Of Florida Treatment for phenylketonuria
WO2005033321A2 (en) 2003-09-30 2005-04-14 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
AU2004290692A1 (en) 2003-11-17 2005-06-02 Biomarin Pharmaceutical Inc. Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin
WO2006073496A2 (en) 2004-07-30 2006-07-13 Targeted Genetics Corporation Recombinant aav based vaccine methods
EP1845952A2 (en) 2004-11-17 2007-10-24 Biomarin Pharmaceutical Inc. Stable tablet formulation of tetrahydrobiopterin
EP2359865B1 (en) 2005-04-07 2013-10-02 The Trustees of The University of Pennsylvania Method of increasing the function of an AAV vector
US8283151B2 (en) * 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7892824B2 (en) 2007-01-18 2011-02-22 University Of Missouri-Columbia Synthetic mini/micro-dystrophin genes to restore nNOS to the sarcolemma
AR066354A1 (es) 2007-05-01 2009-08-12 Genzyme Corp La terapia sistematica con factor-1 de crecimiento de tipo insulina reduce la neuropatia periferica diabetica y mejora la funcion renal en la nefropatia diabetica
MX2010000944A (es) 2007-07-26 2010-08-31 Amsterdam Molecular Therapeutics Bv Vectores baculovirales que comprenden secuencias de codificacion repetida con deformaciones diferenciales en codones.
US7560263B2 (en) 2007-08-17 2009-07-14 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
MX2010007452A (es) 2008-01-07 2010-08-18 Biomarin Pharm Inc Metodo para sintetizar tetrahidrobiopterin.
RU2502800C2 (ru) 2008-01-15 2013-12-27 Эббви Инк. Усовершенствованные векторы экспрессии млекопитающих и их применение
US7943379B2 (en) 2008-04-30 2011-05-17 Nationwide Children's Hospital, Inc. Production of rAAV in vero cells using particular adenovirus helpers
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
HUE061345T2 (hu) 2008-09-15 2023-06-28 Uniqure Biopharma B V IX-es faktor polipeptid mutáns, alkalmazásai és eljárás elõállítására
US10920244B2 (en) * 2009-04-30 2021-02-16 The Trustees Of The University Of Pennsylvania Compositions for targeting conducting airway cells comprising adeno-associated virus constructs
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
KR20180108886A (ko) 2010-03-23 2018-10-04 인트렉손 코포레이션 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도
US20130023033A1 (en) 2010-03-29 2013-01-24 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
MX367100B (es) 2012-02-17 2019-08-05 The Children´S Hospital Of Philadelphia Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos.
GB201210357D0 (en) 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
EP3747998A1 (en) 2013-03-15 2020-12-09 The Trustees of the University of Pennsylvania Compositions for treating mpsi
EP3003391B1 (en) 2013-05-31 2021-09-22 The Regents of The University of California Adeno-associated virus variants and methods of use thereof
HUE047996T2 (hu) 2013-07-22 2020-05-28 Childrens Hospital Philadelphia AAV variáns és készítmények, eljárások és alkalmazások sejtekbe, szervekbe és szövetekbe történõ géntranszferhez
PT3044231T (pt) 2013-09-12 2020-08-27 Biomarin Pharm Inc Vetores de avv compreendendo um gene que codifica o fator viii
NZ758021A (en) * 2013-10-11 2021-12-24 Massachusetts Eye & Ear Infirmary Methods of predicting ancestral virus sequences and uses thereof
EA034103B1 (ru) 2013-10-22 2019-12-27 Транслейт Био, Инк. СПОСОБ ЛЕЧЕНИЯ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
MX2016011686A (es) 2014-03-09 2016-11-07 Univ Pennsylvania Composiciones utiles en el tratamiento de deficiencia de la ornitina transcarbamilasa (otc).
EP2960336A1 (en) 2014-06-27 2015-12-30 Genethon Efficient systemic treatment of dystrophic muscle pathologies
JP6782171B2 (ja) 2014-07-02 2020-11-11 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド メッセンジャーｒｎａのカプセル化
WO2016016119A1 (en) 2014-07-26 2016-02-04 Consiglio Nazionale Delle Ricerche Compositions and methods for treatment of muscular dystrophy
SG10201913259QA (en) 2014-09-24 2020-02-27 Hope City Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
GB201507842D0 (en) 2015-05-07 2015-06-17 New Royal Holloway & Bedford Production of large-sized microdystrophins in an AAV-based vector configuration
AU2016298394C1 (en) 2015-07-30 2024-02-15 Massachusetts Eye And Ear Infirmary Ancestral virus sequences and uses thereof
WO2017053677A1 (en) 2015-09-24 2017-03-30 Biomarin Pharmaceutical Inc. Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same
WO2017066764A2 (en) * 2015-10-16 2017-04-20 William Marsh Rice University Modification of n-terminal region of capsid proteins for enhanced properties of adeno-associated viruses
KR20180069054A (ko) 2015-10-28 2018-06-22 상가모 테라퓨틱스, 인코포레이티드 간-특이적 작제물인, 인자 viii 발현 카세트 및 이의 사용 방법
PE20231949A1 (es) 2015-10-30 2023-12-05 Spark Therapeutics Inc VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA
AU2017391165B2 (en) 2016-11-04 2023-02-02 Takeda Pharmaceutical Company Limited Adeno-associated virus formulations
KR20190100318A (ko) 2016-12-30 2019-08-28 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 페닐케톤뇨증을 치료하기 위한 유전자 치료
EP3746113A4 (en) 2018-02-01 2022-03-09 Homology Medicines, Inc. ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR PAH GENE TRANSFER AND METHODS OF USE
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
TW202016314A (zh) 2018-05-09 2020-05-01 美商拜奧馬林製藥公司 治療苯丙酮尿症之方法
SG11202010832YA (en) 2018-05-14 2020-11-27 Biomarin Pharm Inc Stable expression of aav vectors in juvenile subjects
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US20210355454A1 (en) 2018-07-24 2021-11-18 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
WO2020214929A1 (en) 2019-04-19 2020-10-22 Regenxbio Inc. Adeno-associated virus vector formulations and methods
WO2020232044A1 (en) 2019-05-14 2020-11-19 Biomarin Pharmaceutical Inc. Methods of redosing gene therapy vectors
AR122409A1 (es) 2020-04-03 2022-09-07 Biomarin Pharm Inc Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas

Also Published As

Publication number Publication date
SG11201811603WA (en) 2019-02-27
IL263801B2 (en) 2024-01-01
KR20190032375A (ko) 2019-03-27
US20230322864A1 (en) 2023-10-12
MX2019000962A (es) 2019-08-01
CA3031026A1 (en) 2018-02-01
AU2017301600A1 (en) 2019-01-17
RU2019103983A3 (es) 2021-03-03
IL263801A (en) 2019-01-31
JP2022001064A (ja) 2022-01-06
JP2022033245A (ja) 2022-02-28
EP3491008A2 (en) 2019-06-05
CL2023000165A1 (es) 2023-09-08
BR112019001532A2 (pt) 2019-09-10
US11584780B2 (en) 2023-02-21
PH12019500068A1 (en) 2019-10-21
KR102604510B1 (ko) 2023-11-23
JP7395550B2 (ja) 2023-12-11
RU2019103983A (ru) 2020-08-26
WO2018022608A2 (en) 2018-02-01
JP6994018B2 (ja) 2022-01-14
CL2020003176A1 (es) 2021-06-04
AU2022259813A1 (en) 2022-12-01
IL305149A (en) 2023-10-01
WO2018022608A3 (en) 2018-03-01
CL2023002764A1 (es) 2024-04-05
US20220402974A1 (en) 2022-12-22
CN109715650A (zh) 2019-05-03
CL2019000167A1 (es) 2019-05-24
CN109715650B (zh) 2024-03-08
JP2019525758A (ja) 2019-09-12
AU2017301600B2 (en) 2022-08-04
JP2023076606A (ja) 2023-06-01
JP7303287B2 (ja) 2023-07-04
KR20230161535A (ko) 2023-11-27
PE20190401A1 (es) 2019-03-13
IL263801B1 (en) 2023-09-01
CL2023003010A1 (es) 2024-04-26

Similar Documents

Publication Publication Date Title
CL2023003010A1 (es) Novedosas proteínas de la cápside del virus adenoasociado
AR115097A1 (es) Vectores virales adenoasociados dirigidos al hígado
CL2018000740A1 (es) Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden
CL2018001522A1 (es) Focalización de péptidos para dirigir virus adenoasociados (aavs)
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
CL2019000261A1 (es) Polipéptidos modificados y usos de los mismos.
CL2017001584A1 (es) Anticuerpos antimiostatina, polipéptidos que contienen regiones fc variantes, y métodos de uso
CO2018009995A2 (es) Proteínas de unión y métodos de uso de las mismas
CL2017002731A1 (es) Adenovirus oncolítico que codifica una proteína b7
CO2018012374A2 (es) Moléculas de anticuerpo para el tratamiento del cáncer
CO2018004743A2 (es) Proteínas de unión al antígeno anti-tigit y métodos para usarlas
BR112018011881A2 (pt) proteínas capsidiais modificadas para liberação aumentada de vetores de parvovírus
CO2017012562A2 (es) Vectores virales adenoasociados que codifican para la enzima iduronato-2-sulfatasa
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
ECSP19018654A (es) Anticuerpos contra el virus del dengue, polipeptidos que contienen regiones fc variantes, y métodos de uso
AR104604A1 (es) ANTICUERPOS ANTI-FcRn
CL2019000999A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos.
BR112017005235A2 (pt) vetores virais adeno-associados para o tratamento de glaucoma de miocilina (myoc)
UY36602A (es) Variantes de protoxina-ii y métodos de uso
DK3313864T3 (da) Rekombinante virusvektorer indeholdende prrsv minor protein og fremgangsmåder til fremstilling og anvendelse deraf
AR112904A1 (es) Proteínas de unión a antígenos anti-gitr y métodos para el uso de las mismas
AR108761A1 (es) Arn modificado que codifica polipéptidos de factor de crecimiento endotelial a (vegf-a), formulaciones y usos relacionados con los mismos